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Recently, the diagnostic criteria of preeclampsia have been changed. No studies are available in the literature that analyzed in detail
the differences between early-onset preeclampsia (EOP) and late-onset preeclampsia (LOP), taking into account the International
Society for the Study of Hypertension in Pregnancy (ISSHP) criteria. .us, we sought to retrospectively investigate in detail the
differences in clinical and laboratory outcomes between EOP and LOP diagnosed according to the ISSHP criteria. A retrospective
cohort study was conducted in 214 women with singleton pregnancies and preeclampsia admitted to the Department of Obstetrics
and Perinatology of the University Hospital in Kraków, Poland, from 2013 to 2017 (113 (52.8%) women with EOP and 101 (47.2%)
women with LOP). Electronic medical records were reviewed for demographics and medical history, laboratory tests, and delivery
and neonatal data. Patients with preeclampsia accounted for 1.7% of the women who delivered during the study period. .e EOP
and LOP groups did not differ in the distribution of risk factors for preeclampsia. .e most common risk factor was primiparity,
which was observed in 72.0% of cases. Regarding the ISSHP diagnostic criteria, the two groups differed in the incidence of fetal
growth restriction (p � 0.0009), hemolysis (p � 0.0416), and neurological complications (p � 00342), which were found more
often in the EOP group. In addition, the EOP group had more frequent occurrence of severe cardiorespiratory (p< 0.0001) and
hematological (p � 0.0127) complications, adverse fetoplacental conditions (p< 0.0001), and severe fetoplacental complications
(p � 0.0003). Children born to women with EOP had lower Apgar scores (p< 0.001) and higher rates of intraventricular
hemorrhage (p< 0.0001), respiratory disorders requiring mechanical ventilation (p< 0.0001), and early (p � 0.0004) and late
sepsis (p � 0.002). EOP differed from LOP in terms of maternal and perinatal adverse outcomes. .e observed higher rates of
fetoplacental adverse conditions and severe complications indicate a significant contribution of impaired placentation to the
etiopathogenesis of EOP.
1. Introduction
Preeclampsia is a hypertensive disorder specific to pregnancy.
Over the last decades, the incidence of preeclampsia has in-
creased in some regions worldwide [1]. It complicates up to 5%
of all pregnancies [2, 3] and is associated with serious maternal
complications such as death, stroke, or liver rupture [4–6].
However, there has never been a consensus on the
classification and diagnostic criteria for the hypertensive
disorders of pregnancy. .ere are some differences between
the two leading institutions dealing with the issue of hy-
pertension in pregnancy, namely, American College of
Obstetricians and Gynecologists (ACOG) and International
Society for the Study of Hypertension in Pregnancy (ISSHP)
[7–9], which can lead to differences in their observed rates of
adverse maternal and fetal outcomes. In recent years, both
ACOG and ISSHP have modified the diagnostic criteria for
preeclampsia [7–9]. .ey have excluded the dependence of
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preeclampsia diagnosis on proteinuria. In 2013, ACOG
published a report on hypertension in pregnancy, with fetal
growth restriction (FGR) being eliminated from the con-
sideration of preeclampsia [7]. In 2014, a revised statement
from the ISSHP was published [8, 9]. In this statement,
uteroplacental dysfunctionmanifesting as FGR is considered
one of the preeclampsia diagnostic criteria. Furthermore, the
end-organ dysfunction of preeclampsia, referred to as ad-
verse conditions and severe complications, has been dis-
tinguished. Adverse conditions consist of maternal
symptoms and abnormal laboratory and fetal monitoring
results that may herald the development of severe maternal
or fetal complications. In turn, severe maternal or fetal
complications of preeclampsia are the features that warrant
delivery. Depending on time, the condition is classified as
early-onset preeclampsia (EOP), which requires delivery
before 34weeks’ gestation, or late-onset preeclampsia
(LOP), with delivery at or after 34weeks or later [7–11].
Although the diagnostic criteria for EOP and LOP are
the same, there are some uncertainties about the maternal
and fetal outcomes [12, 13]. It is thought that EOP poses a
high risk to both mother and fetus [14, 15], whereas LOP
may present with less severe clinical symptoms [16]. Many
studies have explored the clinical and laboratory findings in
EOP and LOP. However, they mainly have focused on the
risk factors and selected maternal and neonatal clinical
outcomes as well as selected laboratory findings [17–26].
Moreover, previous studies utilized the diagnostic criteria of
preeclampsia given several years ago.
.erefore, this study aimed to evaluate the differences in
clinical and laboratory findings between patients with EOP
and LOP and to assess whether both forms of the disease met
the same ISSHP diagnostic criteria.
2. Materials and Methods
.is retrospective cohort study included women with
pregnancies and preeclampsia admitted to the Department
of Obstetrics and Perinatology of the University Hospital in
Kraków, Poland, from 2013 to 2017. Preeclampsia was di-
agnosed based on the International Society for the Study of
Hypertension in Pregnancy (ISSHP) guidelines [8, 9]. .e
initial study population consisted of 231 patients with
preeclampsia, accounting for 1.7% of the 13,716 patients
who delivered at our institution from 2013 to 2017. EOP was
diagnosed in 120 patients (52%), and 111 patients (48%)
were diagnosed with LOP. Multiple pregnancies, which
occurred at similar frequencies in the two groups (5.8% and
9.0%, respectively), were excluded from further analyses, and
113 women with EOP and 101 women with LOP were
enrolled.
2.1. Management of Pregnancy Complicated by Preeclampsia
2.1.1. Definitions. Gestational age was determined based on
the date of the last menstrual period and/or the measure-
ment of the crown-rump length in the first trimester of
pregnancy.
Preeclampsia was diagnosed according to the criteria
given in Table 1.
Diagnostic criteria for severe preeclampsia included the
occurrence of severe uncontrolled hypertension (>160/
110mmHg) and any severe neurological, cardiorespiratory,
hematological, renal, hepatic, or fetoplacental complications
[8, 9]. Resistant preeclampsia was defined as the need for
three antihypertensive medications for blood pressure
control at ≥20weeks of gestation [9].
HELLP was diagnosed if the platelet count is <10×109/L,
alanine aminotransaminase (ALT) or aspartate amino-
transferase (AST) >70 IU/L, and lactate dehydrogenase
(LDH) >600 IU/L [10].
In our center, all women with preeclampsia are referred
to the hospital. When possible, on admission to the hospital
with informed consent, a blood sample was collected to
assess blood count, platelet count, and serum levels of
creatinine, blood urea nitrogen, uric acid, and liver enzymes,
and a urine sample was collected and analyzed for pro-
teinuria. Depending on the clinical condition of the patient,
24-hour urine collection was performed if possible to assess
the level of proteinuria. .e number of women in whom
specific measurements have been performed is given in the
tables. Moreover, fetal well-being was evaluated through an
ultrasound examination to determine the estimated fetal
weight, Doppler flow in the umbilical artery (UA) and
middle cerebral artery (MCA), cerebroplacental ratio (CPR),
and nonstress cardiotocographic test (NST). We considered
the pulsatility index (PI) in the UA and MCA as well as
cerebroplacental ratio (CPR�MCA PI/UA PI).
Blood pressure was measured at least four times per day,
and blood samples were collected 1-2 times per week. Fetal
well-being was assessed based on fetal heart rate monitoring
or NST. Ultrasound examination was performed at least
once per week and in cases of Doppler abnormalities, every
three days.
Patients were treated with the antihypertensive drug,
including methyldopa as the first-line therapy. For emer-
gency treatment of preeclampsia, labetalol and/or oral ni-
fedipine were administered. Magnesium sulfate was
administered for neuroprotection and prevention of sei-
zures. Steroid therapy was given for lung maturation be-
tween 24 + 0 and 34 + 0weeks of gestation.
Delivery was indicated in the event of preeclampsia after
37weeks; placental abruption; progressive maternal renal,
liver, neurological, or hematological dysfunction; inability to
control maternal blood pressure despite antihypertensive
medication; or nonreassuring cardiotocography or ultra-
sound-based concerns for fetal well-being or stillbirth.
.e institutional review board waived the requirement
for ethical approval for this analysis since the laboratory and
sonographic evaluations were performed as an integral part
of the routine clinical care, for which informed consent had
been obtained from the women. Data were anonymized.
2.2. Statistical Analysis. Patient characteristics are described
as means with standard deviation for normally distributed
numerical data and as percentages for categorical variables.
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Differences were analyzed by Student’s t-test for normally
distributed data and the Mann–Whitney U-test for non-
normally distributed data. Chi-square and Fisher’s exact tests
were used for comparisons of categorical variables. In all an-
alyses, p values <0.05 were considered statistically significant.
3. Results
.e groups did not differ in terms of distribution of risk
factors for preeclampsia (Table 2). .e most common risk
factor was primiparity, which was present in 72.0% of the
patients. Considering the applied diagnostic criteria, the
groups differed in the incidence of neurological complica-
tions (p � 0.0342), hemolysis (p � 0.0416), and FGR
(p � 0.0009) (Table 3).
On average, preeclampsia was diagnosed at week 30 in
the EOP group and at week 36 in the LOP group. Admission-
to-delivery interval was longer in the EOP group
(8± 8.55 days) than in the LOP group (4± 5.5 days,
p � 0.0002); however, there was no difference in the de-
livery-to-discharge interval (Table 4).
Compared to the LOP group, the EOP group had a
higher proportion of women with severe preeclampsia
(96.4% vs. 87.0%, p � 0.0412), higher mean systolic
(178mmHg vs. 168mmHg, p � 0.005) and diastolic blood
pressure (109mmHg vs. 104mmHg, p � 0.026) on admis-
sion, as well as resistant hypertension (30.0% vs. 2.0%;
p< 0.0001), placental abruption (16.8% vs. 4.0%, p � 0.004),
diagnosis of genitourinary infection (27.4% vs. 15%,
p � 0.0385), and the need for albumin transfusion (19.4% vs.
8.0%, p � 0.019) (Table 4)..ere were significant differences
regarding the frequency of severe cardiorespiratory
(p< 0.0001) and hematological complications (p � 0.0127)
(Table 5). .ere was one maternal death at 28weeks of
gestation because of pulmonary embolism as well as one case
of hysterectomy due to placental abruption and uterine
atony. Furthermore, complications in puerperium occurred
more frequently in the EOP group than in the LOP group
(56.0% vs. 41.6%, p � 0.0375).
All women had significant proteinuria, but patients in
the EOP group were characterized by a significantly higher
level of proteinuria (4.21 g vs. 2.32 g, p � 0.007) (Figure 1),
higher daily protein loss (6.35 g vs. 3.82 g, p � 0.008), and
more frequent daily protein loss ≥10 g (22.3% vs. 11.6%,
p � 0.0122) (Table 6). In addition, the EOP group dem-
onstrated a higher blood urea nitrogen (5.31 vs. 4.88,
p � 0.021) (Figure 2) and serum creatinine concentration
(72.3 vs. 63.0 IU, p � 0.001) (Figure 3 and Table 6).
.e mean gestational age at birth and mean birth weight
were significantly lower in the EOP group than in the LOP
group (p< 0.001) (Table 7). .e indication for delivery was
intrauterine fetal distress in 69.0% of cases in the EOP group
and in 33.0% of cases in the LOP group (p< 0.001) (Table 6).
.e study groups also differed in the prevalence of CPR
below the 5th percentile (70.0% vs. 32.0%, p � 0.001) and
abnormal MCA flow rate, defined as PI <5th percentile
(46.0% vs. 11.0%, p< 0.001). Moreover, compared to the
LOP group, the EOP group had higher rates of FGR, defined
as birth weight <10th (p � 0.001), 5th (p � 0.006), and 3rd
Table 1: Diagnostic criteria for preeclampsia [8].
Blood pressure
Systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg that are noted
twice within 6 hours after 20weeks of gestation in women with normal blood pressure before
conception or in women with previous chronic hypertensive disorders
And coexistence of one or more of the following new-onset conditions
Proteinuria Spot urine protein/creatinine >30mg/mmol (0.3mg/mg) or >300mg/day or at least 1 g/L (“2+”)on dipstick testing
Other maternal organ dysfunctions
(1) Renal insufficiency (creatinine >90 μmol/L; 1.02mg/dL)
(2) Liver involvement (doubling of serum transaminases and/or severe right upper quadrant
pain)
(3) Neurological complications (eclampsia, altered mental status, blindness, stroke, or more
commonly hyperreflexia when accompanied by clonus and severe headaches when
accompanied by hyperreflexia and persistent visual scotomata)
(4) Hematological complications (platelet count <150,000/dL, DIC, and hemolysis)
Uteroplacental dysfunction Fetal growth restriction
DIC, disseminated intravascular coagulation.
Table 2: .e distribution of selected maternal risk factors for
preeclampsia in women with singleton pregnancy and early- or
late-onset preeclampsia.





Primiparity, n (%) 83 (73.4) 71 (70.3) 154 (72.0)
Multiparity (>3), n (%) 3 (2.6) 5 (5.0) 8 (3.7)
Previous preeclamptic
pregnancy, n (%) 2 (1.7) 2 (2.0) 4 (1.8)
Chronic hypertension, n (%) 20 (17.7) 14 (14.0) 34 (15.8)
Chronic renal disease, n (%) 4 (3.5) 2 (2.0) 6 (2.8)
History of thrombophilia, n (%) 2 (1.7) 1 (1.0) 3 (1.4)









Type 1 or type 2 diabetes
mellitus, n (%) 7 (6.2) 8 (8.0) 15 (7.0)
Obesity, BMI >30 kg/m2, n (%) 13 (11.5) 12 (12.0) 25 (11.7)
Systemic lupus
erythematosus, n (%) 1 (0.9) 0 (0.0) 1 (0.4)
Maternal age ≥40 years, n (%) 9 (8.0) 4 (4.0) 13 (6.0)
BMI, body mass index; EOP, early-onset preeclampsia; LOP, late-onset
preeclampsia.
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(p � 0.002) percentiles, and lower Apgar scores in the 1st,
3rd, and 5th minute (all p< 0.001) (Table 7 and Figure 4)..e
risk of birth of a child with an Apgar score <7/10 in the first
minute instead of 10/10 was 7.59 times greater among pa-
tients with EOP than among patients with LOP (RR� 7.59,
95% CI� 3.11 – 18.53). .erefore, fetoplacental adverse
conditions and severe complications were more frequent in
the EOP group (Table 6).
Early preeclampsia was also associated with a higher risk
of perinatal mortality (RR� 1.90, 95% CI: 1.20–3.01). In the






Proteinuria 113 (100.0) 101 (100.0) 214 (100.0) ns
Renal insufficiency
(creatinine >90 μmol/L), n (%) 11 (9.7) 6 (6.0) 17 (7.9) ns
Liver involvement, n (%) 15 (13.3) 8 (7.9) 23 (10.7) ns
Neurological complications, n (%) 20 (17.7) 8 (8.0) 28 (13.0) 0.0342
Hematological complications, n (%) 50 (44.2) 35 (34.6) 85 (39.7) ns
(i) .rombocytopenia, n (%) 37 (74) 29 (82.8) 66 (77.6) ns
(ii) DIC, n (%) 0 (0.0) 2 (5.8) 2 (2.4) ns
(iii) Hemolysis, n (%) 13 (26) 4 (11.4) 17 (20.0) 0.0416
FGR, n (%) 80 (70.7) 49 (48.5) 129 (60.3) 0.0009
DIC, disseminated intravascular coagulation; EOP, early-onset preeclampsia; FGR, fetal growth restriction; ISSHP, International Society for the Study of
Hypertension in Pregnancy; LOP, late-onset preeclampsia; ns, nonstatistically significant.
Table 4: Characteristics and occurrence of adverse maternal outcomes in women with early-onset and late-onset preeclampsia.
EOP (n� 113) LOP (n� 101) Total (n� 214) p





Gestational age at inclusion, weeks± SD (range) 30.0± 2.5 (22.0–33.0) 36.2± 1.4 (34.0–39.3) 33.1± 1.6 (22.0–39.3) 0.00001
Systolic blood pressure on admission, mmHg± SD
(range) 178± 18 (140–240) 168± 18 (120–230) 173± 18 (120–240) 0.005
Diastolic blood pressure on admission, mmHg± SD
(range) 109± 12 (90–150) 104± 11 (70–145) 106± 11 (70–150) 0.026
Antihypertensive drug administration, n (%)
Methyldopa 106 (93.8) 90 (90.0) 196 (94.8) ns
Calcium channel blocker 46 (40.7) 29 (29.0) 75 (35.0) ns
Beta-blocker 65 (57.5) 26 (26.0) 91 (42.5) <0.001
Resistant hypertension, n (%) 34 (30.0) 2 (2.0) 36 (16.8) <0.0001
MgSO4 administered, n (%) 65 (57.5) 30 (30.0) 85 (45.8) <0.001
Admission-to-delivery interval, days± SD (range) 6.8± 6.8 (1–30) 6± 8.5 (1–53) 6± 7.0 (1–53) 0.021
Gestational age at delivery, weeks± SD (range) 30.6± 2.2 (23.0–33.8) 36.6± 1.4 (34.0–39.5) 33.9± 1.9 (23.0–39.5) <0.0001
Delivery-to-discharge interval, days± SD (range) 6.7± 3.5 (3–24) 6.4± 3.6 (3–30) 6.5± 3 (3–30) ns
Severe preeclampsia, n (%) 109 (96.4) 87 (87.0) 196 (91.5) 0.0412
HELLP, n (%) 5 (4.4) 4 (4.0) 9 (4.2) ns
Eclampsia before delivery, n (%) 0 (0.0) 2 (2.0) 2 (0.9) ns
Postpartum eclampsia, n (%) 17 (15.0) 7 (7.0) 24 (11.2) ns
Placental abruption, n (%) 19 (16.8) 4 (4.0) 23 (10.7) 0.004
Hemorrhage, n (%) 3 (2.6%) 1 (1.0) 4 (1.8) ns
Blood transfusion, n (%) 12 (10.6) 7 (7.0) 19 (8.8) ns
Albumin transfusion, n (%) 22 (19.4) 8 (8.0) 30 (14.0) 0.019
Anemia, n (%) 50 (44.2) 40 (40.0) 90 (42.0) ns
Pulmonary edema, n (%) 5 (4.4) 0 (0.0) 5 (2.3) ns
Hysterectomy, n (%) 0 (0.0) 1 (1.0) 1 (0.4) ns
Maternal death, n (%) 1 (0.8) 0 1 (0.4) ns
DIC, n (%) 0 (0.0) 2 (2.0) 2 (0.9) ns
ICU, n (%) 22 (19.4) 6 (6.0) 28 (13.0) 0.02
Uterine contraction disorders, n (%) 3 (2.6) 1 (1.0) 4 (1.8) ns
.rombosis, n (%) 2 (1.7) 4 (4.0) 6 (2.8) ns
Healing disorders of the scar, n (%) 3 (2.6) 6 (6.0) 9 (4.2) ns
Genitourinary infection, n (%) 31 (27.4) 15 (15.0) 46 (21.5) 0.0385
DIC, disseminated intravascular coagulation; EDD, estimated date of delivery; EOP, early-onset preeclampsia; HELLP, hemolysis, elevated liver enzymes, low
platelets; ICU, intensive care unit; LOP, late-onset preeclampsia; ns, nonstatistically significant; SD, standard deviation.
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EOP group, 22 (17.6%) women delivered at <28weeks of
gestation. .ere was one intrauterine death at 24weeks of
gestation, and 13 neonates (11.5%) died during the first
month, of which 10 were born at ≤28weeks and 3 after
28weeks of gestation. All children born at <28weeks of
pregnancy developed respiratory distress syndrome and
needed mechanical ventilation. Compared to the LOP
group, the EOP group also had higher rates of in-
traventricular hemorrhage (27.4% vs. 1.0%, p< 0.0001),
fresh frozen plasma transfusion (p � 0.0002), and early
(p � 0.0004) and late sepsis (p � 0.002) (Table 7).
4. Discussion
To the best of our knowledge, this is among the first studies
that compared the clinical and laboratory outcomes between
EOP and LOP, which were diagnosed according to the new
ISHPP criteria. .is comprehensive cohort study demon-
strates that EOP and LOP do not meet the same diagnostic
criteria. Early-onset preeclampsia poses a high risk of ma-
ternal neurological, cardiorespiratory, and hematological
complications as well as adverse fetoplacental conditions
and complications.
.e incidence of preeclampsia in our department was 1.7%,
which is consistent with the observation in the Chinese
population [27] but lower than that reported in another report
[17]. .is relatively low prevalence of preeclampsia may be
because our department is a tertiary referral center and admits
mainly pregnant women at risk of giving birth before 32weeks
of gestation as well as the most severe cases, which accounted
for 96.4% of patients in the EOP group and 87% of patients in
the LOP group (p � 0.0412). On the other hand, such a low
percentage of pregnancies complicated by preeclampsia may
result from ethnic conditions. It has been shown that there is a
higher percentage of preeclampsia in the African American
race than in theChinese population [27]..ePolish population
and our cohort are characterized by the fact that they are
homogeneous of the Caucasian race. Another explanation may
be that, in Poland, women are covered by medical care before
the 10th week of pregnancy, andmedical appointments are held
at least every 4weeks. Another issue is the possibility of di-
versity in diet and vitamin supplementation.
.e exact cause of preeclampsia is unknown, but ma-
ternal and placental factors are considered to be involved in
the etiology of the disease. It has been suggested that EOP is
more strongly associated with internal placental factors
[28, 29], whereas the late-onset form may be primarily due
to predisposing maternal factors. Although the present
study did not find any differences between the two groups
with respect to risk factors for preeclampsia, a previous
study by Lisonkova and Joseph [17] found that older
maternal age, unmarried status, and male sex of infant are
typical to EOP and LOP, whereas African American race,
chronic hypertension, and congenital anomalies are
strongly associated with EOP [17]. Moreover, in the study
by Aksornphusitaphong and Phupong [15], history of
chronic hypertension was significantly associated with
increased risk for only EOP, whereas a family history of
chronic hypertension was associated with increased risk for
only LOP. It is worth mentioning that patients in the
studied population were predominantly primipara, which
is known to be a major risk factor for preeclampsia [7].
It is thought that EOP may have a more severe course
than LOP [8]. .e incidence of placental abruption, overall
mortality, and FGR have been shown to depend on the
severity and duration of preeclampsia [30–34]. Our study
did identify differences in the frequency of neurological
complications and severe cardiorespiratory and hemato-
logical complications between the EOP and LOP groups.
.ese findings are different from those of the studies by
Pettit et al. [13] and Madazil et al. [19].
Table 5: Adverse conditions and severe complications in women with early-onset and late-onset preeclampsia.
Organ system
affected











CNS, n (%) 3 (2.6) 17 (15.0) 1 (1.0) 7 (7.0) ns ns
Cardiorespiratory, n (%) 2 (1.7) 34 (30.0) 1 (1.0) 2 (2.0) ns <0.0001
Hematological, n (%) 37 (32.7) 24 (21.2) 29 (29.0) 9 (9.0) ns 0.0127
Renal, n (%) 15 (13.2) 2 (1.7) 8 (8.0) 1 (1.0) ns ns
Hepatic, n (%) 15 (13.2) 0 (0.0) 8 (8.0) 0 (0.0) ns ns
Fetoplacental, n (%) 87 (77.0) 21 (18.5) 42 (42.0) 3 (3.0) <0.0001 0.0003



















Figure 1: Proteinuria in women with early- and late-onset pre-
eclampsia. EOP, early-onset preeclampsia; LOP, late-onset
preeclampsia.
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Table 6: Laboratory measurements in women with early-onset and late-onset preeclampsia.
EOP (n)∗, mean± SD LOP (n)∗, mean± SD p
Proteinuria (g/L) (n� 80)4.21± 6.84
(n� 58)
2.32± 3.61 0.007
Proteinuria, n (%) (91) (78)
≤5 g/day, n (%) 53 (58.2) 59 (75.6) ns
5.1–9.9 g/day, n (%) 16 (17.6) 10 (12.8) ns
≥10 g/day, n (%) 22 (24.2) 9 (11.6) 0.0122
24-hour urine proteinuria (g/24 h) (n� 91)6.35± 8.23
(n� 78)
3.82± 4.36 0.008
Blood urea nitrogen (mmol/L) (n� 75)5.31± 1.93
(n� 62)
4.88± 3.14 0.021
Uric acid (µmol/L) (n� 30)418.1± 107.6
(n� 25)
389.6± 82.3 ns
Creatinine (µmol/L) (n� 78)72.3± 31.2
(n� 56)
63.0± 34.4 0.001
Creatinine clearance (ml/min) (n� 16)102.8± 48.0
(n� 15)
127.8± 74.1 ns
Total serum protein (g/L) (n� 71)55.8± 6.0
(n� 48)
57.7± 7.21 ns
Albumin (g/L) (n� 50)29.2± 4.28
(n� 30)
31.5± 6.74 ns
Hemoglobin (g/L) (n� 113)12.3± 1.49
(n� 92)
12.3± 1.33 ns
Hematocrit (%) (n� 113)35.6± 4.3
(n� 92)
35.8± 3.7 ns
Erythrocytes (×109/L) (n� 113)4.05± 0.47
(n� 92)
4.04± 0.42 ns
Platelet (×109/L) (n� 113)184.0± 72.8
(n� 92)
178.0± 68.9 ns
Alanine aminotransaminase (U/L) (n� 73)43.4± 48.2
(n� 50)
70.9± 141.0 ns
Aspartate aminotransferase (U/L) (n� 73)44.8± 53.3
(n� 50)
65.2± 134.9 ns




























Figure 2: Blood urea nitrogen of women with early- and late-onset























Figure 3: Creatinine of women with early- and late-onset pre-
eclampsia. EOP, early-onset preeclampsia; LOP, late-onset
preeclampsia.
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Interestingly, in our observation, the EOP group had
higher serum levels of renal biomarkers than the LOP group,
but no differences were found between the groups in terms
of adverse renal conditions and severe complications.
However, renal function can be impaired throughout pre-
eclampsia as a result of glomerular endotheliosis, leading to a
decrease in the glomerular filtration rate [35]. In the present
study, the groups differed in terms of proteinuria, blood urea
nitrogen, and serum creatinine levels, which are represen-
tative of renal function in pregnancy. In contrast to our
study, Weitzner et al. [25] did not show differences in
creatinine levels. Furthermore, the increased serum level of
uric acid has been shown to correlate with the severity of
glomerular endotheliosis [36]. However, in our study, the
groups did not differ in terms of uric acid concentration, in
contrast to a previous report by Li et al. comparing EOP and
LOP in patients with severe hypertension [18].
In our observation, EOP was strongly associated with
adverse fetoplacental conditions and severe complications.
.e cause of impaired fetoplacental function may be the
abnormal invasion of trophoblasts and remodeling of the
spiral arteries, which can result in limited blood flow and lead
to growth restriction and fetal distress symptoms. In our
study, FGR occurred in 60.2% of all pregnancies complicated
by preeclampsia, which is consistent with the study ofMadazil
et al. [19], which reported a rate of 59.1%. Furthermore, in the
present study, the incidence of fetal growth restriction
reached as much as 70.7% in pregnancies with EOP. .is
finding is consistent with the report of Lisonkova and Joseph
[17], but not with other observations [18]. Interestingly, the
studied groups did not differ in terms of the frequency of flow
disturbances in the UA, but in the EOP group, there were
more frequent flow disturbances in the MCA. CPR <5th
percentile also occurred more frequently in the EOP group.
Both our study and Sibai’s study [30] showed a 100% mor-
tality rate in children born before 28weeks of pregnancy.
Compared to other papers, the major strength of the
present work is that it contains a detailed, extensive analysis of
clinical and laboratory factors that could be collected from the
medical records. However, our study also has several limi-
tations. First, it is a retrospective observational study with a
relatively small sample size. Moreover, in some cases, due to
the severity of the disease, it became necessary to terminate
the pregnancy within a short period of time, which did not
permit further laboratory testing. Finally, the hospital where
the study was conducted is a tertiary referral center, wherein
the most severe cases from the region of south-eastern Poland
are treated; hence, it could affect the results.
Table 7: Fetal factors associated with early- and late-onset preeclampsia.
EOP (n� 113) LOP (n� 101) Total (n� 214) p
Gestational age at delivery, weeks± SD (range) 30.6± 2.2 (23.0–33.8) 36.6± 1.4 (34.0–39.5) 33.9± 1.9 (23.0–39.5) <0.0001
Birth weight (g), mean± SD (range) 1358± 497 (460–3450) 2511± 689 (1010–4320) 1934± 592 (460–4320) <0.001
Fetal sex
Female, n (%) 63 (56.0) 53 (52.0) 116 (54.0) ns
Male, n (%) 50 (44.0) 48 (48.0) 98 (46.0) ns
Intrauterine fetal distress, n (%) 78 (69.0) 33 (33.0) 111 (51.8) <0.001
UA PI >95th percentile, n (%) 27 (23.9) 15 (15.0) 42 (19.6) ns
MCA PI <5th percentile, n (%) 52 (46.0) 11 (11.0) 63 (29.4) <0.001
CPR <5th percentile, n (%) 79 (70.0) 32 (32.0) 111 (51.8) 0.001
FGR <10th percentile, n (%) 80 (70.7) 49 (49.0) 129 (60.2) 0.0015
FGR <5th percentile, n (%) 71 (62.8) 46 (46.0) 117 (54.6) 0.006
FGR <3rd percentile, n (%) 66 (58.4) 37 (37.0) 103 (48.1) 0.002
Apgar score at 1min, mean± SD (range) 6.7± 1.9 (1–10) 9.1± 1.4 (1–10) 7.9± 1.5 (1–10) <0.001
Apgar score at 3min, mean± SD (range) 7.4± 1.7 (1–10) 9.6± 0.7 (7–10) 8.5± 1.4 (1–10) <0.001
Apgar score at 5min, mean± SD (range) 7.8± 1.3 (4–10) 9.8± 0.6 (7–10) 8.8± 1.3 (4–10) <0.001
Apgar score <7 at 1min, n (%) 51 (45.0) 4 (4.0) 55 (25.7) <0.001
Apgar score <7 at 3min, n (%) 27 (23.9) 2 (2.0) 29 (13.5) <0.001
Apgar score <7 at 5min, n (%) 19 (16.8) 0 (0.0) 19 (8.8) <0.001
Intrauterine fetal death, n (%) 1 (0.9) 0 (0.0) 1 (0.4) ns
IVH, n (%) 31 (27.4) 1 (1.0) 32 (14.9) <0.0001
FFP transfusion, n (%) 15 (13.3) 0 (0.0) 15 (7.0) 0.0002
Mechanical ventilation 33 (29.2) 1 (1.0) 34 (15.9) <0.0001
Infection complications, n (%)
Early sepsis 18 (16.0) 1 (1.0) 19 (8.8) 0.0004
Late sepsis 20 (17.7) 2 (2.0) 22 (10.2) 0.0021
Retinopathy, n (%) 2 (1.8) 0 (0.0) 2 (0.9) ns
NEC, n (%) 3 (2.6) 0 (0.0) 3 (1.4) ns
Fetal death, n (%) 13 (11.5) 0 (0.0) 13 (6.0) 0.0008
Born ≤28weeks 10 (8.8) 0 (0.0) 0.0058
Born >28weeks 3 (2.6) 0 (0.0) ns
CPR, cerebroplacental ratio; FFP, fresh frozen plasma; FGR, fetal growth restriction; IVH, intraventricular hemorrhage; MCA, middle cerebral artery; NEC,
necrotizing enterocolitis; ns, nonstatistically significant; PI, pulsatility index; RDS, respiratory distress syndrome; SD, standard deviation; UA, umbilical
artery; EOP, early-onset preeclampsia; LOP, late-onset preeclampsia.
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In summary, EOP differed from LOP mainly in terms of
adverse maternal and fetoplacental conditions and severe
complications. .e observed higher rates of FGR and vas-
cular flow disturbances indicate a significant contribution of
impaired placentation to the etiopathogenesis of the early
form of preeclampsia. .e obtained results indicate that we
should pay attention to the neurological, cardiorespiratory,
and hematological parameters as well as to the intensive fetal
surveillance in women with EOP.
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